Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Show more

Location: 200-3650 Gilmore Way, Burnaby, BC, V5G 4W8, Canada | Website: https://www.xenon-pharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.561B

52 Wk Range

$26.74 - $46.00

Previous Close

$33.37

Open

$33.70

Volume

492,420

Day Range

$33.06 - $33.83

Enterprise Value

1.861B

Cash

549.6M

Avg Qtr Burn

-49.21M

Insider Ownership

0.14%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XEN1101 Details
Epilepsy, Seizures, Primary Generalized Tonic Clonic Seizures

Phase 3

Data readout

XEN1101 (Potassium Channel Modulator) Details
Epilepsy, Focal Onset Seizures

Susp. Mover™

Phase 3

Data readout

XEN1101 Details
Mental health, Major depressive disorder

Phase 3

Initiation

Azetukalner (XEN1101) Details
Epilepsy, Focal Onset Seizures

Phase 2b

Update

XEN901/NBI-921352 Details
Epilepsy, Focal Onset Seizures

Phase 2

Update

Phase 1

Initiation

IND

Submission

Failed

Discontinued

Failed

Discontinued